多巴胺受体激动剂普拉克索治疗原发性不宁腿综合征

Efficacy of dopamine receptor agonist pramipexole in patients with primary restless legs syndrome

目的观察普拉克索治疗原发性不宁腿综合征(RLS)的临床疗效及安全性。方法选取2013年10月至2015年9月煤炭总医院神经内科收治的原发性RLS患者60例,随机分为治疗组及对照组,每组各30例患者。治疗组患者给予口服普拉克索治疗,对照组患者给予美多芭联合劳拉西泮治疗,疗程12周。以不宁腿严重程度量表(IRLS)、匹兹堡睡眠质量指数(PSQI)和汉密尔顿焦虑量表(HAMA)分别作为疾病严重程度、睡眠质量和焦虑障碍程度的指标,进行疗效评估。同时,观察普拉克索治疗的不良反应,并评价其安全性。结果治疗组IRLS、PSQI、HAMA评分较治疗前均明显下降(P<0.05)。对照组IRLS、HAMA评分均较治疗前明显下降(P<0.05);PSQI评分虽然较治疗前下降,但差异无统计学意义(P>0.05)。治疗后,普拉克索组IRLS、PSQI、HAMA评分明显低于对照组(P<0.05),提示普拉克索不但可以显著改善RLS患者运动症状,同时具有良好的改善睡眠状态、抗焦虑情绪的作用。本研究中普拉克索不良反应主要是早期出现胃部不适,困倦感,症状轻微,无需停药,可自行缓解。结论普拉克索单独治疗可以显著改善RLS患者运动症状,同时具有改善睡眠状态、抗焦虑情绪的作用,且耐受性良好,可以作为治疗不宁腿综合征的有效药物。

Objective To observe the effect of pramipexole on the treatment of primary restless legs syndrome（ RLS）. Methods Totally 60 patients with primary RLS were randomly divided into the treatment group（ n = 30） and the control group（ n = 30）. The treatment group was given pramipexole for 12 weeks while the control group was given madopar plus lorazepam. The international RLS study group rating scale（ IRLS）,Pittsburgh Sleep Quality Index（ PSQI） and Hamilton Anxiety Scale（ HAMD） were used to evaluate the effect. Results The treatment group showed significant improvement compared with control group. IRLS,PSQI and HAMA for patients declined in various degrees,and the differences were significant（ P 〈 0. 05）. Conclusion Pramipexole can not only effectively improve RLS but also improve the sleep quality and ease anxiety with low adverse reaction in RLS patients.